Tagged with Switzerland,

Switzerland The Chairman of Ferring’s Group Operating Committee and Senior Vice President Europe-Canada elaborates on how Europe can be the thinking engine for global pharmaceutical trends.   Ferring has bundled the European and Canadian markets into one single region. Could you please introduce us to the full scope of your role…

Switzerland An expert in the implementation of Swiss federal laws within Switzerland’s constituent cantons, Giovan Maria Zanini discusses the evolution of Swiss pharma regulatory framework and efforts to strengthen and protect the country’s world leading innovation environment.  Dr. Zanini, you have been described as “the expert in the cantonal implementation of…

Switzerland Switzerland may have a world class healthcare system, but small adjustments are needed to ensure incentives for payer and providers are properly aligned with the patient’s ultimate quality and value of care. Dr. Cassis, could you please introduce yourself, with reference to your experience and current responsibilities in the realm…

Switzerland Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem –  the largest and most advanced peptide drug CMO in the world. Peptide therapeutics are a hot topic in the pharma industry today – what’s the story…

Switzerland Outsourcing of API synthesis has stabilized in the decade since Rohner Chem entered the pharma sector in earnest, and according to CEO Daniel Pedrett the company has reached a position where it is faster, more agile and more experienced than the internal supply organizations of many mid-sized innovators. You were…

Switzerland Helsinn is a leader in cancer supportive care, and Vice Chairman and CEO Riccardo Braglia enthusiastically discusses the Group’s entrance into the field of oncology therapeutics and the launch of the new Helsinn Investment Fund.   Helsinn Advanced Synthesis in Biasca is a very advanced site capable of synthesizing high…

Switzerland With over 50 years of history in Switzerland, Zambon operates in Canton Ticino one of Zambon’s two major global production centers. Swiss Market  Manager Giampiero Roncoroni discusses the unique features of the Swiss market, and how a particular focus on the OTC/OTX market has been a key factor of success…

Switzerland With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity and finding opportunities for growth. Could you please briefly introduce yourself and B Braun Switzerland to our readers? B Braun…

Switzerland Sintetica, Switzlerland’s longtime leader in local anesthesia and pain relief with development efforts in neuromodulation, started an ambitious internationalization strategy in 2011. CEO Augusto Mitidieri discusses the company’s expansion progress and highlights areas of unmet medical need around anesthetics. What are the most significant unmet medical needs in the realm…

Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development.  Switzerland of course has quite the reputation as a hub for biotech activity – how…

Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…

Switzerland Developing manufacturing capacity for as yet unapproved drugs can create huge risk on innovators’ balance sheets, risk which can be mitigated by working instead with a competent CMO – a form of insurance as explained by Siegfried CEO Rudolf Hanko.   The CMO sector has grown faster than the pharma…